Detection, distribution and inhibition of Branhamella catarrhalis beta-lactamases - PubMed (original) (raw)
Detection, distribution and inhibition of Branhamella catarrhalis beta-lactamases
A Philippon et al. Drugs. 1986.
Abstract
Beta-lactamase-producing isolates of Branhamella catarrhalis were first detected in France in 1977. The frequency of beta-lactamase producers has increased, especially since 1980. An agar iodometric test, a fast chromogenic test and an acidimetric test were used to assess the beta-lactamase-producing capabilities of 188 isolates of B. catarrhalis obtained mainly from sputum and the pharynx. Data from the first 2 procedures indicated positive beta-lactamase activity for all 49 strains of B. catarrhalis identified, but there were some discrepancies in the acidimetric test results. Evidence from a diffusion technique showed significant increases in the inhibition diameters surrounding filter discs impregnated with amoxycillin in the presence of clavulanic acid, or with ampicillin in the presence of sulbactam, compared with discs of the penicillins used alone. Two types of enzyme activity emerged from examination of isoelectric focusing patterns. Type I, having pI values of 5.35, 5.55 and 5.85, accounted for 87.2% of the enzyme-producing isolates. Type II, with pIs of 5.5, 5.9 and 6.25, occurred in 12.8% of isolates and appeared to be less widely distributed. The beta-lactamase inhibitors clavulanic acid and sulbactam in combination with benzylpenicillin produced potentiated effects, as demonstrated by significant reductions in MIC (33- and 44-fold decreases, respectively). Higher concentrations of each inhibitor similarly affected the MICs of amoxycillin. A weak synergy occurred with cefoxitin, a beta-lactamase-resistant beta-lactam antibiotic, and the 2 beta-lactamase inhibitors. Because B. catarrhalis has been shown to be a beta-lactamase-producing pathogenic organism, the addition of enzyme inhibitors, such as clavulanic acid and sulbactam, to standard therapy may be beneficial.
Similar articles
- [Sulbactam and clavulanic acid: studies of enzyme kinetics and synergism with ampicillin and mezlocillin].
Cullmann W, Binder S, Stieglitz M. Cullmann W, et al. Immun Infekt. 1987 May;15(3):103-9. Immun Infekt. 1987. PMID: 3038733 German. - Inhibition of the beta-lactamases of Branhamella catarrhalis by clavulanic acid and other inhibitors.
Farmer T, Reading C. Farmer T, et al. Drugs. 1986;31 Suppl 3:70-8. doi: 10.2165/00003495-198600313-00015. Drugs. 1986. PMID: 3488199 - Beta-lactamase inhibitors from laboratory to clinic.
Bush K. Bush K. Clin Microbiol Rev. 1988 Jan;1(1):109-23. doi: 10.1128/CMR.1.1.109. Clin Microbiol Rev. 1988. PMID: 3060240 Free PMC article. Review. - Evolution of beta-lactamase inhibitors.
Rolinson GN. Rolinson GN. Rev Infect Dis. 1991 Jul-Aug;13 Suppl 9:S727-32. doi: 10.1093/clinids/13.supplement_9.s727. Rev Infect Dis. 1991. PMID: 1656513 Review.
Cited by
- Molecular characterization of the beta-lactamases from clinical isolates of Moraxella (Branhamella) catarrhalis obtained from 24 U.S. medical centers during 1994-1995 and 1997-1998.
Richter SS, Winokur PL, Brueggemann AB, Huynh HK, Rhomberg PR, Wingert EM, Doern GV. Richter SS, et al. Antimicrob Agents Chemother. 2000 Feb;44(2):444-6. doi: 10.1128/AAC.44.2.444-446.2000. Antimicrob Agents Chemother. 2000. PMID: 10639381 Free PMC article. - Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.
McGregor K, Chang BJ, Mee BJ, Riley TV. McGregor K, et al. Eur J Clin Microbiol Infect Dis. 1998 Apr;17(4):219-34. doi: 10.1007/BF01699978. Eur J Clin Microbiol Infect Dis. 1998. PMID: 9707304 Review. - [Moraxella catarrhalis: virulence and resistance mechanisms].
Cullmann W. Cullmann W. Med Klin (Munich). 1997 Mar 15;92(3):162-6. doi: 10.1007/BF03043274. Med Klin (Munich). 1997. PMID: 9173208 Review. German. - Molecular characterization of the BRO beta-lactamase of Moraxella (Branhamella) catarrhalis.
Bootsma HJ, van Dijk H, Verhoef J, Fleer A, Mooi FR. Bootsma HJ, et al. Antimicrob Agents Chemother. 1996 Apr;40(4):966-72. doi: 10.1128/AAC.40.4.966. Antimicrob Agents Chemother. 1996. PMID: 8849261 Free PMC article. - Evaluation of amoxicillin clavulanate twice daily versus thrice daily in the treatment of otitis media in children. Danish-Swedish Study Group.
Jacobsson S, Fogh A, Larsson P, Lomborg S. Jacobsson S, et al. Eur J Clin Microbiol Infect Dis. 1993 May;12(5):319-24. doi: 10.1007/BF01964426. Eur J Clin Microbiol Infect Dis. 1993. PMID: 8354296 Clinical Trial.
References
- Lancet. 1978 Jul 29;2(8083):257 - PubMed
- Ann Microbiol (Paris). 1978 Oct;129 B(3):397-406 - PubMed
- Ann Biol Clin (Paris). 1977;35(2):73-87 - PubMed
- Ann Microbiol (Paris). 1981 Jul-Aug;132B(1):23-39 - PubMed
- Lancet. 1977 Dec 3;2(8049):1175 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous